Robert Gagnon Sells 28,000 Shares of Opus Genetics (NASDAQ:IRD) Stock

Opus Genetics, Inc. (NASDAQ:IRD) CFO Robert Gagnon sold 28,000 shares of Opus Genetics stock in a transaction dated Thursday, September 3rd. The stock was sold at an average price of $4.54, for a total transaction of $127,120.00. Following the transaction, the chief financial officer directly owned 556,375 shares of the company’s stock, valued at approximately $2,525,942.50. This represents a 4.79% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Opus Genetics Trading Up 32.0%

Shares of NASDAQ:IRD opened at $5.73 on Thursday. Opus Genetics, Inc. has a 12 month low of $1.32 and a 12 month high of $7.07. The company has a market capitalization of $473.58 million, a price-to-earnings ratio of -4.24 and a beta of 0.58. The firm’s 50-day moving average is $3.82 and its 200 day moving average is $4.30.

Opus Genetics (NASDAQ:IRD) last announced its quarterly earnings data on Thursday, August 6th. The company reported ($0.14) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.16) by $0.02. Opus Genetics had a negative net margin of 1,091.82% and a negative return on equity of 338.88%. The business had revenue of $0.76 million during the quarter, compared to the consensus estimate of $2.63 million. As a group, equities analysts forecast that Opus Genetics, Inc. will post -0.99 EPS for the current fiscal year.

Trending Headlines about Opus Genetics

Here are the key news stories impacting Opus Genetics this week:

• Positive Sentiment: Opus Genetics reported that all five patients in the low-dose cohort of its Phase 1/2 BIRD-1 trial showed clinically meaningful improvement in visual function. Three of five patients experienced meaningful best-corrected visual-acuity improvement, while retinal sensitivity improved in three of four evaluable patients. No serious adverse events or dose-limiting toxicities were observed. Opus Genetics Announces Positive Low Dose Cohort 1 Data
• Positive Sentiment: The company said its FDA Type C meeting produced alignment around a potential pivotal endpoint, and it plans to complete Cohort 2 dosing in the fourth quarter of 2026, report three-month data in the second quarter of 2027, and potentially begin Phase 3 dosing in 2027. Opus expects cash resources to extend into 2029.
• Positive Sentiment: Analyst sentiment strengthened: Oppenheimer raised its price target to $20 from $10 and maintained an outperform rating; Wedbush raised its target to $13 from $10; and BTIG, Chardan and HC Wainwright reaffirmed buy ratings with targets of $12, $13 and $8, respectively. Wedbush Price Target Update
• Positive Sentiment: Unusually heavy call-option activity—4,820 calls purchased versus typical volume of 617—signals elevated speculative bullish interest, although it may also amplify volatility.
• Neutral Sentiment: CFO Robert Gagnon sold 28,000 shares worth $127,120 to cover tax withholding tied to equity vesting. The sale reduced his holdings by 4.79%, but the stated tax-related purpose makes it a limited standalone signal.

Wall Street Analysts Forecast Growth

IRD has been the subject of a number of recent analyst reports. Weiss Ratings restated a “sell (d-)” rating on shares of Opus Genetics in a report on Friday, July 17th. Wall Street Zen upgraded Opus Genetics from a “sell” rating to a “hold” rating in a research note on Sunday, August 16th. Royal Bank Of Canada decreased their target price on Opus Genetics from $10.00 to $9.00 and set an “outperform” rating for the company in a research report on Friday, August 7th. Guggenheim began coverage on shares of Opus Genetics in a research note on Thursday, June 4th. They set a “buy” rating and a $16.00 target price for the company. Finally, Citizens Jmp restated a “market outperform” rating and issued a $11.00 price target on shares of Opus Genetics in a report on Monday, June 15th. One equities research analyst has rated the stock with a Strong Buy rating, fifteen have given a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, Opus Genetics has an average rating of “Moderate Buy” and an average price target of $11.69.

Institutional Investors Weigh In On Opus Genetics

Several large investors have recently modified their holdings of the business. Occudo Quantitative Strategies LP bought a new position in shares of Opus Genetics during the fourth quarter valued at approximately $25,000. Comerica Bank bought a new position in Opus Genetics in the first quarter worth approximately $29,000. Virtu Financial LLC bought a new position in Opus Genetics in the fourth quarter worth approximately $34,000. Raymond James Financial Inc. raised its stake in Opus Genetics by 95.6% in the third quarter. Raymond James Financial Inc. now owns 22,508 shares of the company’s stock worth $37,000 after buying an additional 11,000 shares in the last quarter. Finally, Johnson Investment Counsel Inc. purchased a new stake in Opus Genetics during the fourth quarter worth $40,000. Institutional investors own 14.97% of the company’s stock.

About Opus Genetics

Opus Genetics Inc is a clinical-stage ophthalmic biopharmaceutical company, focuses on developing and commercializing therapies for the treatment of unmet needs of patients with refractive and retinal eye disorders. Opus Genetics Inc, formerly known as Ocuphire Pharma Inc, is based in Farmington Hills, Michigan.